"10.1371_journal.pone.0139439","plos one","2015-10-13T00:00:00Z","Anita KÃ¥ss; Ivana Hollan; Morten Wang Fagerland; Hans Christian Gulseth; Peter Abusdal Torjesen; Ã˜ystein Torleiv FÃ¸rre","Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Rheumatology, Betanien Hospital, Skien, Norway; Department of Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Unit of Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway; Hormone Laboratory, Oslo University Hospital, Oslo, Norway; Department of Rheumatology, Oslo University Hospital, Oslo, Norway","Conceived and designed the experiments: AK. Performed the experiments: AK HCG. Analyzed the data: AK MWF IH Ã˜TF. Contributed reagents/materials/analysis tools: PAT. Wrote the paper: AK Ã˜TF MWF HCG PAT IH.","I have read the journals policy and the authors of this manuscript have the following competing interests: AK patent application on GnRH antagonists: a. Methods of treating inflammatory disease, patent application number 62110731; b. Methods of treating rheumatoid arthritis, patent application number 61943787. Although we strictly did not receive funding or scientific input from Aeterna Zentaris, they did agree to supply the Cetrorelix free of charge. This does not alter our adherence to PLOS ONE policies on sharing data materials. We have no other competing interests to declare.","2015","10","Anita KÃ¥ss","AKÃ",6,TRUE,1,2,4,6,TRUE,TRUE,TRUE,1,"6",TRUE
